ÂÜÀòÂÒÂ×

Dr. Curley brings more than twenty-five years of experience in the development and commercialization of pharmaceutical products, including R&D governance.

Dr. Curley joined Vera from Gilead Sciences, Inc., where she led Project and Portfolio Management with oversight for the development pipeline across four therapeutic areas. During her 15-year tenure at Gilead the anti-viral portfolio grew from four to 15 commercial products.

Prior to Gilead, Curley worked as a formulation scientist and subsequently as a project leader at Nektar Therapeutics.

She received a BSc in Physics/Chemistry from Trinity College, Ireland, a PhD in Polymer Science and Engineering from the University of Massachusetts, Amherst and did a post-doctorate at MIT and Harvard Medical School, focused on long-acting biodegradable formulations.